Apotex Health seeks to raise up to C$1.2 billion, potentially reviving Toronto IPO market

• Apotex plans to offer between 41.7 million and 50 million shares, raising roughly C$850 million through new issuance
• The Toronto IPO market has seen only a handful of listings in recent years, with companies avoiding the subdued market, though renewed economic confidence and a rising TSX are spurring fresh interest
• Major underwriters include RBC Capital Markets, TD Securities, Scotiabank, BMO Capital Markets, and Jefferies as joint bookrunners

Apotex Health IPO Targets C$1.2 Billion in Toronto Market Revival

Canadian healthcare company Apotex Health announced plans Monday to raise up to C$1.2 billion ($868 million) through an initial public offering on the Toronto Stock Exchange, marking one of 2026's first major TSX listings.

Key Deal Details:

• Offering between 41.7 million and 50 million shares
• Company raising approximately C$850 million through new share issuance
• Underwriters include RBC Capital Markets, TD Securities, Scotiabank, BMO Capital Markets, and Jefferies

Company Profile:

Apotex serves clients in approximately 70 countries across North and South America, focusing primarily on generic pharmaceuticals. The company has demonstrated steady growth with revenue increasing roughly 8% over the past four fiscal years, driven by its core generics business, first-to-market product strategy, and expansion into higher-value segments including specialty generics, branded products, and biosimilars.

Market Implications:

This IPO could signal a revival of Toronto's subdued IPO market, which has seen only a handful of listings in recent years as companies avoided unfavorable market conditions. Renewed economic confidence and a rising TSX have sparked fresh interest from companies across technology, natural resources, and other sectors. Earlier this year, Toronto-based Xanadu Quantum Technologies raised approximately $300 million through a SPAC merger, listing on both Nasdaq and the TSX.

The successful execution of Apotex's offering could encourage other Canadian companies to pursue public listings, potentially reinvigorating capital markets activity in Toronto after an extended quiet period.